Literature DB >> 3030781

Opposite effects of mu and kappa opiates on the firing-rate of dopamine cells in the substantia nigra of the rat.

J M Walker, L A Thompson, J Frascella, M W Friederich.   

Abstract

Single unit extracellular recording was carried out in rats to compare the actions of a mu receptor agonist (morphine) to a kappa receptor agonist (U50,488) in the substantia nigra pars compacta (SNC). Intravenously administered morphine and U50,488 exhibited opposite effects: morphine excited SNC dopamine cells, and U50,488 inhibited them. Both effects were blocked by naloxone, although significantly more naloxone was necessary to block the effect of the kappa agonist. Local administration of U50,488 in the caudate also inhibited the firing of SNC dopamine cells. These results are discussed in terms of the natural functions of the prodynorphinergic straiatonigral projection.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3030781     DOI: 10.1016/0014-2999(87)90130-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  16 in total

1.  Methamphetamine-induced stereotypy correlates negatively with patch-enhanced prodynorphin and arc mRNA expression in the rat caudate putamen: the role of mu opioid receptor activation.

Authors:  Kristen A Horner; Erika S Noble; Yamiece E Gilbert
Journal:  Pharmacol Biochem Behav       Date:  2010-03-15       Impact factor: 3.533

2.  Voluntary ethanol intake predicts κ-opioid receptor supersensitivity and regionally distinct dopaminergic adaptations in macaques.

Authors:  Cody A Siciliano; Erin S Calipari; Verginia C Cuzon Carlson; Christa M Helms; David M Lovinger; Kathleen A Grant; Sara R Jones
Journal:  J Neurosci       Date:  2015-04-15       Impact factor: 6.167

3.  Effects of kappa opioid receptor agonists on fentanyl vs. food choice in male and female rats: contingent vs. non-contingent administration.

Authors:  E Andrew Townsend
Journal:  Psychopharmacology (Berl)       Date:  2021-01-06       Impact factor: 4.530

4.  Effects of kappa receptor agonists on D1 and D2 dopamine agonist and antagonist-induced behaviors.

Authors:  C Marin; T M Engber; P Chaudhuri; A Peppe; T N Chase
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

5.  Activation of mu opioid receptors in the striatum differentially augments methamphetamine-induced gene expression and enhances stereotypic behavior.

Authors:  Kristen A Horner; John C Hebbard; Anna S Logan; Golda A Vanchipurakel; Yamiece E Gilbert
Journal:  J Neurochem       Date:  2012-01-23       Impact factor: 5.372

6.  Increased presynaptic regulation of dopamine neurotransmission in the nucleus accumbens core following chronic ethanol self-administration in female macaques.

Authors:  Cody A Siciliano; Erin S Calipari; Jordan T Yorgason; David M Lovinger; Yolanda Mateo; Vanessa A Jimenez; Christa M Helms; Kathleen A Grant; Sara R Jones
Journal:  Psychopharmacology (Berl)       Date:  2016-02-19       Impact factor: 4.530

7.  Heightened aggressive behavior during morphine withdrawal: effects of d-amphetamine.

Authors:  J W Tidey; K A Miczek
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

8.  Antagonism of the morphine-induced Straub tail reaction by kappa-opioid receptor activation in mice.

Authors:  M Narita; T Suzuki; M Misawa; H Nagase
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

9.  Attenuation of cocaine-induced reinstatement of drug seeking in squirrel monkeys: kappa opioid and serotonergic mechanisms.

Authors:  Daniela Rüedi-Bettschen; James K Rowlett; Roger D Spealman; Donna M Platt
Journal:  Psychopharmacology (Berl)       Date:  2009-10-27       Impact factor: 4.530

10.  The effects of the kappa agonist U-50,488 on cocaine-induced conditioned and unconditioned behaviors and Fos immunoreactivity.

Authors:  C A Crawford; S A McDougall; C A Bolanos; S Hall; S P Berger
Journal:  Psychopharmacology (Berl)       Date:  1995-08       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.